Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2022-08-02 Regulatory Filings
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2022-08-02 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the resubmission of a New Drug Application (NDA) for treosulfan to the FDA, including details about the clinical trial results, expected FDA decision timeline, and potential commercial impact. It does not contain financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. It is primarily an update on a regulatory submission and business development related to drug approval. This type of document fits best under the category of Capital/Financing Update (CAP) because it relates to a significant regulatory milestone that impacts the company's capital and commercial prospects, rather than a formal financial report or regulatory filing. The document length (8977 characters) and content confirm it is not a brief announcement or certification but a substantive update. Therefore, the most appropriate classification is CAP with high confidence.
2022-07-25 English
Notice of the meeting and record date - French.pdf
AGM Information Classification · 95% confidence The document is a notification regarding the upcoming Annual General Meeting (AGM) of Medexus Pharmaceuticals Inc. It provides details such as the type of meeting (Annual General Meeting), registration dates for voting, meeting date, and location. The document is short (1313 characters) and serves as an announcement about the AGM rather than the AGM materials or minutes themselves. Therefore, it fits best under the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM or related announcements about the AGM.
2022-07-05 English
Notice of the meeting and record date - English.pdf
AGM Information Classification · 95% confidence The document is a notice from Computershare to Canadian Securities Regulatory Authorities regarding the upcoming Annual General Meeting (AGM) of Medexus Pharmaceuticals Inc. It provides details about the meeting date, record dates, meeting type, and proxy material distribution. The document does not contain financial data, management discussion, or detailed report content. It is an announcement related to the AGM, specifically about the meeting logistics and proxy materials. Given the short length (1168 characters) and the nature of the content, this fits the category of AGM Information (AGM-R) rather than the full Annual Report or Proxy Solicitation materials.
2022-07-05 English
52-109F1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F1 Certification of Annual Filings Full Certificate by the CFO of Medexus Pharmaceuticals Inc. It certifies the review and fair presentation of the annual filings for the financial year ended March 31, 2022. The document focuses on the certification of disclosure controls and internal control over financial reporting (ICFR) as required by National Instrument 52-109. It does not contain actual financial statements or substantive financial data but is an officer certification related to the annual filings. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than the Annual Report (10-K) or other financial reports.
2022-06-23 English
52-109F1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F1 Certification of Annual Filings Full Certificate signed by the CEO of Medexus Pharmaceuticals Inc. It certifies the review and fair presentation of the annual filings for the financial year ended March 31, 2022, including the AIF, annual financial statements, and annual MD&A. The document focuses on the certification of disclosure controls and internal control over financial reporting (ICFR) as required by National Instrument 52-109. It does not contain the actual annual report or financial statements but is a formal attestation by the CEO regarding the accuracy and completeness of those filings. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than the actual Annual Report (10-K) or Management Discussion & Analysis (MDA). The document length is 4550 characters, which is relatively short and consistent with a certification letter rather than a full report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2022-06-23 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.